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Purpose
Adjuvant chemoradiation following primary surgery is frequently indicated in patients with
stage IB cervical cancer. The aim of this study is to evaluate the role of a magnetic resonance
imaging (MRI)-based strategy in avoiding trimodality therapy.
Materials and Methods
We retrospectively reviewed all patients with stage IB cervical cancer treated initially with
primary surgery at Seoul National University Hospital. We suggest an alternative triage strat-
egy in which the primary treatment modality is determined based on preoperative MRI find-
ings. Using this strategy, primary surgery is only indicated when there is no evidence of
parametrial involvement (PMI) and lymph node metastasis (LNM) in the MRI results; when
there is evidence of either or both of these factors, primary chemoradiation is selected. 
Assuming that this strategy is applied to our cohort, we evaluate how the rate of trimodality
therapy is affected.
Results
Of the 254 patients in our sample, 77 (30.3%) had at least one category 1 risk factor (PMI,
LNM, positive resection margin) upon pathologic examination. If the MRI-based strategy
had been applied to our cohort, 168 patients would have undergone primary surgery and
86 would have undergone primary chemoradiation. Only 25 patients (9.8%) would have 
required trimodality therapy based on an indication of at least one category 1 pathologic
risk factor following radical hysterectomy.
Conclusion
The inclusion of MRI in the decision-making process for primary treatment modality could
have reduced the number of patients requiring trimodality therapy based on the indication
of a category 1 risk factor from 30.3% to 9.8% in our cohort. 
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Introduction
Cervical cancer is the third most common female malig-
nancy worldwide and the most common female genital tract
malignancy in Korean women [1,2]. The primary means of
treating early-stage cervical cancer is either surgery or radi-
ation therapy. Surgery is preferred for lower-stage disease
with smaller lesions, such as stage IA, IB1, and selected IIA1,
as ovarian and vaginal function can be preserved [3,4]. For
patients with stage IB2 or IIA2 disease, primary chemoradi-
ation is preferable to radical hysterectomy followed by adju-
vant chemoradiation—known as trimodality therapy—as the
latter has a higher morbidity rate [5-7]. 
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To avoid morbidity resulting from trimodality therapy,
primary surgery should be limited to patients with the low-
est possible risk of needing adjuvant therapy. The Interna-
tional Federation of Gynecology and Obstetrics (FIGO)
staging system is based on clinical staging, including visual
inspection, colposcopy, cervical biopsy, and manual pelvic
examination, and limits the imaging to chest radiography,
intravenous pyelography, and barium enema [8]. However,
a considerable proportion of patients with clinical stage IB
cervical cancer already have pathologic risk factors, such as
parametrial involvement (PMI) or lymph node metastasis
(LNM), before surgery. In stage IB2 and IIA2 cervical cancer
in particular, more than half of patients undergo postopera-
tive adjuvant therapy following primary radical surgery
[9,10]. Although it is not accepted as part of the formal stag-
ing procedure, the use of advanced imaging techniques, such
as magnetic resonance imaging (MRI), computed tomogra-
phy (CT), and positron emission tomography (PET)-CT, has
been suggested as a means of guiding treatment options and
design for cervical cancer patients [11-13].
We developed a decision-analytic model to determine the
role of the triage strategy based on preoperative MRI find-
ings in a cohort of patients with clinical stage IB cervical can-
cer. The aim of this study is to evaluate how the rate of
trimodality therapy is affected when this alternative triage
strategy is used.
Materials and Methods
1. Patients
After receiving approval from the Institutional Review
Board, all patients treated surgically for FIGO stage IB 
cervical cancer between 2003 and 2011 at Seoul National 
University Hospital were reviewed retrospectively. The use
of MRI in diagnosis and follow-up has been widespread at
this institution since 2003. Patients eligible for inclusion were
those: (1) with stage IB cervical cancer and clinically visible
lesions; (2) who had undergone primary radical hysterec-
tomy followed by tailored adjuvant therapy; and (3) who had
a preoperative MRI up to 4 weeks before surgery. Patients
who had undergone radiation therapy or chemotherapy 
before surgery or conization before MRI were excluded. 
Consequently, 254 patients were eligible for analysis. We 
included 190 cases from a previous study of ours published
in 2014 [14]. 
2. MRI and image analysis
The MRI data were reviewed by a radiologist (J.Y.C.), who
was blind to surgical outcomes. The same rating scale for
PMI suggested in a previous study was used [14,15]. A lesion
observed in MRI findings was considered positive when a
pelvic or para-aortic lymph node (LN) displayed a short-axis
dimension ! 1 cm. Any LN measuring 1 cm or marginally
less, giving an overall equivocal impression, was considered
negative.
Patients were categorized according to two groups based
on MRI-based parameters: a low-risk group (no evidence of
PMI and LNM in MRI) and a high-risk group (findings 
suggesting PMI and/or LNM in MRI). 
3. Decision-analysis model
We developed a decision-analysis model to compare the
rate of trimodality therapy for stage IB cervical cancer 
patients when two different strategies were employed (1) a
primary surgery strategy, in which radical surgery and
pelvic lymphadenectomy is recommended to all patients;
and (2) an MRI-based strategy, in which primary treatment
modality is recommended according to risk criteria based on
preoperative MRI results. Under the latter, patients classified
as low risk based on MRI findings were assumed to undergo
primary radical surgery followed by tailored adjuvant ther-
apy, and those classified as high risk were assumed to 
undergo primary chemoradiation. In addition, we analyzed
the number of MRIs that would need to be performed in
order to spare one patient from undergoing trimodality ther-
apy. 
4. Adjuvant therapy following primary surgery
All patients were assumed to undergo adjuvant treatment
in line with their pathologic risk factors. Patients with at least
one category 1 risk factor (positive resection margin, LNM,
or PMI) received adjuvant chemoradiation. Patients with two
or more category 2 risk factors (positive lymphovascular
space invasion, deep stromal invasion, or large tumor size)
received adjuvant chemoradiation. Guideline adherence to
adjuvant treatment was assumed to be 100%.
Results
The characteristics of the study population are summa-
rized in Table 1. The median age was 49 years (range, 25 to
78 years) and 64 patients with stage IB2 were included. Squa-
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mous cell carcinoma was the most prevalent histologic 
subtype (71.3%), followed by adenocarcinoma (22.0%) and
adenosquamous carcinoma (5.1%). Of all patients, 18.1% (46
patients) had MRI findings indicating PMI and 23.2% (59 
patients) had MRI findings suggesting LNM.
A decision tree comparing the two strategies for newly 
diagnosed, stage IB cervical cancer patients is shown in 
Fig. 1. Under the primary surgery strategy, all patients would
have undergone radical hysterectomy and pelvic lym-
phadenectomy (in reality, all 254 patients in our cohort 
underwent primary surgery regardless of the MRI findings).
Of the total study population, 77 patients (30.3%) would have
undergone adjuvant chemoradiation based on at least one
category 1 pathologic risk factor. Conversely, under the 
alternative, MRI-based strategy, 168 patients (66.1%) classi-
fied as low risk based on their MRI findings would have 
undergone primary radical surgery followed by tailored 
adjuvant therapy, and 86 patients (33.9%) classified as high
risk would have undergone primary chemoradiation. Only
25 patients would have required adjuvant chemoradiation
based on at least one category 1 pathologic risk factor follow-
ing surgery, while of the 143 low-risk patients who did not
have category 1 pathologic risk factors, 33 (23.1%) would
have required adjuvant chemoradiation based on two or
more category 2 risk factors. 
Comparison of the rates of trimodality therapy when the
two strategies are applied to our cohort is shown in Table 2.
For stage IB disease, considering MRI findings when decid-
ing between primary surgery or primary chemoradiation
could reduce the rate of trimodality therapy based on at least
one category 1 risk factor from 30.3% to 9.8% and increase
the proportion of patients not undergoing trimodality ther-
apy from 50.4% to 77.2%. For patients with stage IB2 disease,
this effect was particularly prominent. Using MRI-based
triage in these cases could reduce the proportion of patients
requiring trimodality therapy based on category 1 risk 
factors from 54.7% to 10.9% and increase the proportion of
patients not undergoing trimodality therapy from 14.1% to
70.3%. From this, we can deduce that 4.9 MRIs would have
had to be performed in order to spare one patient from 
trimodality therapy in stage IB cervical cancer.
Discussion
For early-stage cervical cancer, initial treatment options 
include primary surgery followed by tailored adjuvant ther-
apy and primary chemoradiation. The current National
Comprehensive Cancer Network (NCCN) guidelines recom-
mend basing the primary treatment option on tumor size for
stage IB cervical cancer patients [16]. Surgery is the preferred
option for patients with stage IB1 disease, whereas primary
chemoradiation is the most appropriate option for those with
stage IB2 disease. However, in practice, primary surgery 
followed by tailored adjuvant therapy is the preferred and
most frequently used treatment modality for stage IB2 
patients [17-19]. Therefore, a considerable proportion of 
patients undergo adjuvant therapy following surgery and
risk high morbidity rates as a result of trimodality therapy
[10,20,21]. If the MRI-based strategy had been applied to our
cohort, 168 patients would have undergone primary surgery
and 86 would have undergone primary chemoradiation.
Only 25 patients (9.8%) would have required trimodality
therapy based on the indication of at least one category 1
pathologic risk factor following radical hysterectomy.
Only a single randomized controlled trial (RCT) has com-
pared the outcomes of primary surgery and primary radio-
therapy [7]. This study did not find greater survival rates for
either treatment modality, however an increase in toxicity
was observed following the combined use of radical 
hysterectomy and adjuvant radiation. To date, no RCT 
comparing the outcomes of primary surgery and primary
chemoradiation has been conducted, however small retro-
spective case-control studies reported no significant differ-
ence in outcomes between the two treatment options [10,21].
Although several investigators have shown that primary 
surgery followed by tailored adjuvant therapy improves out-
comes in the era of chemoradiation, it is generally accepted
that outcomes of either modality in treating early-stage 
Table 1. Baseline characteristics
MRI, magnetic resonance imaging.
Variable No. (%)
Median age (range, yr) 49 (25-78)
Clinical stage
IB1 190 (74.8)
IB2 64 (25.2)
Histology
Squamous cell carcinoma 181 (71.3)
Adenocarcinoma 56 (22.0)
Adenosquamous carcinoma 13 (5.1)
Others 4 (1.6)
MRI-based parameters
Parametrial involvement
No 208 (81.9)
Yes 46 (18.1)
Lymph node metastasis
No 195 (76.8)
Yes 59 (23.2)
disease are comparable [9,22]. The Korean Gynecologic 
Oncology Group (KGOG) 1029 trial is currently recruiting
patients with bulky early-stage cervical cancer in order to
compare the outcomes of primary surgery and primary
chemoradiation. 
Some studies insist that primary surgery continues to play
a significant role in treatment of patients with stage IB cervi-
cal cancer and even bulky stage IB2 disease. Park et al. [9] 
reported that 29.3% of patients with tumors > 4 cm were
cured by surgery alone, and such patients have the best 
survival outcomes and lowest morbidity rates by avoiding
radiation therapy. Therefore, in the preoperative stage we
should identify the subset of patients with stage IB2 disease
who may benefit from surgery alone. 
In the absence of conclusive RCTs that determine the best
treatment option for patients with bulky cervical cancer, 
restricting primary surgery to patients who can be treated
successfully with surgery alone may be the most reasonable
option. With this in mind, we should consider the best triage
strategy for determining when primary surgery is an option
and when primary chemoradiation is preferable, thus avoid-
ing trimodality therapy for patients with stage IB cervical
cancer. Previous studies have suggested that trimodality
therapy is associated with high morbidity rates compared to
surgery alone and primary chemoradiation as well as serious
toxicity frequencies > 20% [7,10,23]. Considering the compli-
cation rates of trimodality therapy, we suggest that primary
surgery should be the initial treatment option for patients
who are less likely to have adjuvant therapy, while primary
chemoradiation is preferable for those who are likely to have
to undergo adjuvant therapy following surgery. Preoperative
prediction models are required for accurate allocation of 
primary treatment options for patients with stage IB disease. 
Under an alternative, MRI-based strategy, the rate of 
trimodality therapy based on category 1 and 2 risk factors
would be reduced, especially for stage IB2 disease. However,
the proportion of patients who undergo surgery alone under
an MRI-based strategy (n=110, 43.3%) is less than under a
primary surgery strategy (n=128, 50.4%). This is the main
weakness of the MRI-based strategy: 7.1% of patients would
not benefit from a purely surgical treatment modality and
would instead undergo primary chemoradiation. MRI-based
strategy has inherent weakness from inaccurate prediction
for PMI and LNM. Regarding detection of metastatic lymph
nodes, the recent meta-analysis shows that PET/CT has
higher accuracy than MRI [24]. Our model based on preop-
erative MRI findings may need to be updated with addition
of PET/CT parameters.
This study has some limitations. First, our model has some
limitations. In this model, the benefit of primary surgery 
followed by tailored adjuvant therapy may be underesti-
mated.  For the simplicity of the model, we did not consider
unstaged para-aortic LNM and salvage therapy after 
primary chemoradiation. Major drawbacks of primary con-
current chemoradiation are unstaged para-aortic LNM based
on preoperative imaging study and salvage therapy from
Stage IB cervical cancer
Primary surgery strategy
MRI-based strategy
Surgery to all patients
254/254 (100%)
No category 1 risk factor
177/254 (69.7%)
Category 1 risk factor (at least 1)
77/254 (30.3%)
Low risk based on MRI
  → Surgery
168/254 (66.1%)
High risk based on MRI
  → Primary chemoradiation
86/254 (33.9%)
No category 2 risk factor (1 or less)
128/177 (72.3%)
Category 2 risk factor (2 or more)
49/177 (27.7%)
No category 2 risk factor (1 or less)
110/143 (76.9%)
Category 2 risk factor (2 or more)
33/143 (23.1%)
No category 1 risk factor
143/168 (85.1%)
Category 1 risk factor (at least 1)
25/168 (14.9%)
No category 1 risk factor
34/86 (39.5%)
Category 1 risk factor (at least 1)
52/86 (60.5%)
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Fig. 1.  A decision tree comparing the two strategies (primary surgery strategy and magnetic resonance imaging [MRI]–
based strategy) for stage IB cervical cancer. Category 1 risk factors: positive resection margin, lymph node metastasis, para-
metrial involvement; category 2 risk factors: positive lymphovascular space invasion, deep stromal invasion, large tumor
size.
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residual disease after completion of treatment. Second, the
results were not validated in an independent set. The 
proportion of pathologic risk factors in stage IB disease varies
according to the patient dataset and therefore affects the 
proportion of patients who require adjuvant therapy follow-
ing surgery. Third, although predicting PMI and LNM using
MRI gives accurate preoperative information, there is the
possibility of inter-observer variation. To minimize this, all
images were re-reviewed. Fourth, the current guidelines do
not recommend using MRI as a universal preoperative
means of evaluation for cervical cancer patients. Finally, 
despite reduced long-term gastrointestinal toxicity, espe-
cially in the postoperative adjuvant setting, radiation deliv-
ery techniques such as intensity-modulated radiation ther-
apy were not considered. 
Despite its limitations, the alternative triage strategy pro-
posed in this paper has some key advantages. Marnitz et al.
[25] suggest that laparoscopic staging is the best means for
selection of patients for either primary chemoradiation or
primary surgery and avoiding trimodality therapy. Radical
hysterectomy was performed only in patients without 
evidence of LNM in the frozen section during laparoscopic
Table 2. Rate of multimodality therapy when the two strategies are applied to stage IB cervical cancer patients
Patient No. (%) Change (%)
Stage IB (n=254)
Primary surgery strategy
Undergoing primary surgery 254 (100) -
Requiring trimodality therapy due to at least one category 1 risk factor 77 (30.3) -
Requiring trimodality therapy due to two or more category 2 risk factor 49 (19.3) -
Not undergoing trimodality therapy 128 (50.4) -
MRI-based strategy
Undergoing primary surgery 168 (66.1) –33.9
Requiring trimodality therapy due to at least one category 1 risk factor 25 (9.8) –20.5
Requiring trimodality therapy due to two or more category 2 risk factor 33 (13.0) –6.3
Not undergoing trimodality therapy 196 (77.2) 26.8
Stage IB1 (n=190)
Primary surgery strategy
Undergoing primary surgery 190 (100) -
Requiring trimodality therapy due to at least one category 1 risk factor 42 (22.1) -
Requiring trimodality therapy due to two or more category 2 risk factor 29 (15.3) -
Not undergoing trimodality therapy 119 (62.6) -
MRI-based strategy
Undergoing primary surgery 141 (74.2) –25.8
Requiring trimodality therapy due to at least one category 1 risk factor 18 (9.5) –12.6
Requiring trimodality therapy due to two or more category 2 risk factor 21 (11.1) –4.2
Not undergoing trimodality therapy 151 (79.5) 16.9
Stage IB2 (n=64)
Primary surgery strategy
Undergoing primary surgery 64 (100) -
Requiring trimodality therapy due to at least one category 1 risk factor 35 (54.7) -
Requiring trimodality therapy due to two or more category 2 risk factor 20 (31.3) -
Not undergoing trimodality therapy 9 (14.1) -
MRI-based strategy
Undergoing primary surgery 27 (42.2) –57.8
Requiring trimodality therapy due to at least one category 1 risk factor 7 (10.9) –43.8
Requiring trimodality therapy due to two or more category 2 risk factor 12 (18.8) –12.5
Not undergoing trimodality therapy 45 (70.3) 56.2
Category 1 risk factors: positive resection margin, lymph node metastasis, parametrial involvement; category 2 risk factors:
positive lymphovascular space invasion, deep stromal invasion, large tumor size. MRI, magnetic resonance imaging.
staging. The authors show that the rate of trimodality ther-
apy based on pathologic risk factors was 10% and suggest
that this percentage could be used as a benchmark for the
quality of interdisciplinary treatment for patients diagnosed
with cervical cancer. By employing the MRI-based strategy,
we can anticipate a low rate of trimodality therapy following
primary surgery without performing laparoscopic staging.
Conclusion
In addition to maintaining the proportion of patients who
could be treated using surgery alone, reducing morbidity
arising from trimodality therapy should be a goal. Preoper-
ative MRI provides useful information for determining the
primary treatment modality for stage IB cervical cancer 
patients. Including MRI in the decision-making process may
reduce morbidity arising from trimodality therapy in 
patients with early-stage cervical cancer. Further studies are
needed in order to validate our results and a cost-effective-
ness analysis should be performed, including the cost of MRI
and complications arising from trimodality therapy.
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